Drug Repurposing for COVID-19 Treatment by Integrating Network Pharmacology and Transcriptomics
Open Access
- 14 April 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (4), 545
- https://doi.org/10.3390/pharmaceutics13040545
Abstract
Since coronavirus disease 2019 (COVID-19) is a serious new worldwide public health crisis with significant morbidity and mortality, effective therapeutic treatments are urgently needed. Drug repurposing is an efficient and cost-effective strategy with minimum risk for identifying novel potential treatment options by repositioning therapies that were previously approved for other clinical outcomes. Here, we used an integrated network-based pharmacologic and transcriptomic approach to screen drug candidates novel for COVID-19 treatment. Network-based proximity scores were calculated to identify the drug–disease pharmacological effect between drug–target relationship modules and COVID-19 related genes. Gene set enrichment analysis (GSEA) was then performed to determine whether drug candidates influence the expression of COVID-19 related genes and examine the sensitivity of the repurposing drug treatment to peripheral immune cell types. Moreover, we used the complementary exposure model to recommend potential synergistic drug combinations. We identified 18 individual drug candidates including nicardipine, orantinib, tipifarnib and promethazine which have not previously been proposed as possible treatments for COVID-19. Additionally, 30 synergistic drug pairs were ultimately recommended including fostamatinib plus tretinoin and orantinib plus valproic acid. Differential expression genes of most repurposing drugs were enriched significantly in B cells. The findings may potentially accelerate the discovery and establishment of an effective therapeutic treatment plan for COVID-19 patients.Keywords
Funding Information
- National Natural Science Foundation of China (81570807)
- National Institutes of Health (U19AG05537301, R01AR069055, P20GM109036, R01MH104680, R01AG061917, U54MD007595)
This publication has 70 references indexed in Scilit:
- Uncovering disease-disease relationships through the incomplete interactomeScience, 2015
- Phase I study on the safety, pharmacokinetic profile, and efficacy of the combination of TSU-68, an oral antiangiogenic agent, and S-1 in patients with advanced hepatocellular carcinomaInvestigational New Drugs, 2014
- High-Throughput Methods for Combinatorial Drug DiscoveryScience Translational Medicine, 2013
- clusterProfiler: an R Package for Comparing Biological Themes Among Gene ClustersOMICS: A Journal of Integrative Biology, 2012
- Drug Discovery Using Chemical Systems Biology: Repositioning the Safe Medicine Comtan to Treat Multi-Drug and Extensively Drug Resistant TuberculosisPLoS Computational Biology, 2009
- Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profilesProceedings of the National Academy of Sciences of the United States of America, 2005
- The beneficial effects of treatment with tamoxifen and anti‐oestradiol antibody on experimental systemic lupus erythematosus are associated with cytokine modulationsImmunology, 1997
- Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)The New England Journal of Medicine, 1991
- NicardipineDrugs, 1987
- Establishment and characterization of a human acute monocytic leukemia cell line (THP‐1)International Journal of Cancer, 1980